Impelix Health builds a remote patient monitoring platform for fluid overload, the proximate driver of hospitalization in heart failure and decompensated cirrhosis. Roughly 6–7 million adults in North America live with clinically significant fluid retention from these conditions. Outpatient monitoring today relies on daily weight and clinic visits weeks apart. Weight is a late, non-specific signal that depends on patient adherence. Peripheral fluid, by contrast, can be measured directly at the ankle. Our platform pairs a wearable sensor using proprietary segmental ankle bioimpedance spectroscopy with a clinician dashboard and a nurse-led monitoring workflow. It tracks each patient's extracellular fluid trajectory against their own baseline and flags deviations for clinician review. It does not diagnose or recommend treatment. We sell Device-as-a-Service: hardware at nominal cost, with recurring revenue tied to existing remote physiologic monitoring reimbursement codes. Practice-level economics are modeled to be accretive under current fee-for-service rules; no new payment pathway is required. Impelix Health Inc. was incorporated federally in March 2026. Our first-in-patient feasibility study (IMP-FEAS-001), a longitudinal design in hospitalized heart failure patients, is being prepared for ethics submission at CISSS des Laurentides, Québec, led by our cardiologist co-founder. We are pursuing a Health Canada Class II licence and U.S. FDA 510(k) clearance in parallel, with an ISO 13485-aligned quality system in place from inception. The founding team combines internal medicine and cardiology practice, biomedical engineering experience in impedance-based medical devices, and product and regulatory leadership. Our systematic review of wearable bioimpedance in heart failure was published in 2025. We are building clinical, regulatory, and investor relationships ahead of a pre-seed round in spring 2027.